PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma by L. Valenti et al.
PNPLA3 I148M Polymorphism, Clinical Presentation, and
Survival in Patients with Hepatocellular Carcinoma
Luca Valenti1,2*, Benedetta Maria Motta1, Giorgio Soardo3, Massimo Iavarone4, Benedetta Donati1,
Angelo Sangiovanni4, Alessia Carnelutti3, Paola Dongiovanni1, Raffaela Rametta1, Cristina Bertelli2,
Floriana Facchetti4, Massimo Colombo1,4, Silvia Fargion1,2, Anna Ludovica Fracanzani1,2
1Department of Pathophysiology and Transplantation, Universita` degli Studi di Milano, Milano, Italy, 2 Internal Medicine, Fondazione Istituto di Ricovero e Cura a
Carattere Scientifico (IRCCS) Ca’ Granda - Ospedale Maggiore Policlinico Milano, Milano, Italy, 3 Internal Medicine, Universita` di Udine, Udine, Italy, 4 First Diviosion of
Gastroenterology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca’ Granda - Ospedale Maggiore Policlinico Milano, Milano, Italy
Abstract
Background & Aims: Aim of this study was to evaluate whether the PNPLA3 I148M polymorphism, previously associated
with hepatocellular carcinoma (HCC) risk, influences the clinical presentation of HCC and survival.
Methods: we considered 460 consecutive HCC patients referred to tertiary care centers in Northern Italy, 353 with follow-up
data.
Results: Homozygosity for PNPLA3 148M at risk allele was enriched in HCC patients with alcoholic liver disease or
nonalcoholic fatty liver disease (ALD&NAFLD: relative risk 5.9, 95% c.i. 3.5–9.9; other liver diseases: relative risk 1.9, 95% c.i.
1.1–3.4). In ALD&NAFLD patients, the PNPLA3 148M allele was associated with younger age, shorter history of cirrhosis, less
advanced (Child A) cirrhosis at HCC diagnosis, and lower HCC differentiation grade (p,0.05). Homozygosity for PNPLA3
148M was associated with reduced survival in the overall series (p = 0.009), and with a higher number of HCC lesions at
presentation (p = 0.007) and reduced survival in ALD&NAFLD patients (p = 0.003; median survival 30, 95% c.i. 20–39 vs. 45,
95% c.i. 38–52 months), but not in those with HCC related to other etiologies (p = 0.86; 48, 95% c.i. 32–64 vs. 55, 95% c.i. 43–
67 months). At multivariate Cox regression analysis, homozygosity for PNPLA3 148M was the only negative predictor of
survival in ALD&NAFLD patients (HR of death 1.57, 95% c.i. 1.12–2.78).
Conclusions: PNPLA3 148M is over-represented in ALD&NAFLD HCC patients, and is associated with occurrence at a less
advanced stage of liver disease in ALD&NAFLD. In ALD&NAFLD, PNPLA3 148M is associated with more diffuse HCC at
presentation, and with reduced survival.
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Introduction
Hepatocellular carcinoma (HCC) is most frequently related to
cirrhosis resulting from chronic liver diseases caused by hepatitis B
and C viruses, alcohol, obesity, and rare genetic disorders.
Environmental toxins, diabetes, and family history represent
common predisposing factors [1], but genetic variants have also
been demonstrated to modify HCC susceptibility [2].
In particular, the rs738409 C.G polymorphism, encoding for
the functional I148M protein variant in the patatin-like phospho-
lipase domain-containing 3 (PNPLA3, adiponutrin) gene has been
associated with the risk of developing HCC [3,4,5,6,7,8,9,10]. The
I148M PNPLA3 polymorphism is the major genetic determinant
of hepatic fat content and liver enzymes in the general population
[11,12,13]. Furthermore, the 148M risk allele favors disease
progression in nonalcoholic fatty liver disease (NAFLD) [14,15],
alcoholic liver disease (ALD) [16,17], chronic hepatitis C (HCV)
[4,18], and also in liver diseases unrelated to steatosis [19,20].
Interestingly, the I148M polymorphism affects HCC risk inde-
pendently of the effect on fibrosis [4,5,6,7,10,21], suggesting that it
has a direct carcinogenic effect by modulating lipid metabolism or
inflammatory mediators [3,5,6,7,8,9]. Furthermore, incorporation
of the I148M polymorphism in model scores improved HCC risk
stratification in patients with alcoholic cirrhosis [8], thereby
representing an attractive biomarker for individualization of the
clinical management of ALD.
However, the implications of PNPLA3 genotype for patients
already diagnoses with HCC are still unknown, as only
preliminary and controversial data are available on the influence
of I148M polymorphism on the clinical presentation and outcome
of HCC [9,22].
We hypothesized that PNPLA3 I148M predisposes to a specific
carcinogenic pathway associated with dysregulation of hepatic
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lipid metabolism [23,24,25], resulting in HCC with distinct
biological features. Therefore, aim of this study was to evaluate
whether the I148M polymorphism is associated with the clinical
presentation and survival in a series of HCC patients from
Northern Italy.
Materials and Methods
Patients
In this retrospective-prospective study, we considered 460
patients with HCC diagnosed at, or referred to, tertiary referral
centers in Northern Italy, for whom DNA samples and clinical
data were available. Most of the patients were diagnosed during
regular screening for chronic liver disease (369/460, 80%). The
case series included 254 consecutive patients evaluated or treated
at the Internal Medicine service, University of Milan, between
January 2000 and June 2012, 120 consecutive patients treated at
the Internal Medicine service, University of Udine between
January 2011 and June 2012, and 86 patients treated at the
Gastroenterology service, University of Milan, between January
2010 and June 2012. HCC was diagnosed according to the
European and American scientific associations guidelines
[26,27,28]. Before 2001 we considered only patients with
histological diagnosis of HCC. Fifty/460 (11%) of the described
patients were included in a previous study from our group [4].
For each patient we recorded the age at diagnosis, gender,
presence / absence of cirrhosis, year of diagnosis of cirrhosis and
of HCC, Child-Pugh classification of cirrhosis, presence of
diabetes, daily alcohol intake. The etiology of liver disease was
classified as related to HCV, chronic HBV infection (HBV), HBV
+ HCV, ALD, NAFLD, hereditary hemochromatosis (HH), or
cryptogenic; based on clinical history, daily alcohol intake,
physical examination, and assessment of viral markers (including
HBsAg, anti-HBc antibodies, and HCV-RNA) in all patients. This
series did not include patients with liver disease related to
autoimmune liver disease, Wilson disease, or alpha1-anti-trypsin
deficiency. In the presence of viral infection, patients were
classified as HBV or HCV even if cofactors (such as obesity, at
risk alcohol intake, or autoimmunity) were present. Patients were
classified as affected by cryptogenic liver disease if viral markers
were negative, and no iron overload or history of obesity, at risk
alcohol intake, or known genetic diseases were present (even if
burn-out NASH could not be excluded). The body mass index was
not considered because of the confounding effect of cachexia and
fluid retention in patients with advanced disease.
The number of HCC lesions at diagnosis, the size of the single
or of the major HCC lesion at diagnosis, Barcelona Clinic Liver
Cancer (BCLC) HCC stage at diagnosis (0, A–B, or C–D),
prospective follow-up with recording of time of death or liver
transplantation was available in 356 patients (77%). Evaluation of
Edmonson histological grade of HCC at diagnosis was available in
118 patients [29].
In the case of remission, follow-up was carried up at 3–6 months
or shorter intervals according to the clinical requirements of the
patients. No patient was lost at follow-up. The time of death was
confirmed by telephone calls with the relatives of the patients.
Data were censored at the time of death or liver transplantation
(15 patients were transplanted) or July 1st, 2012.
Patients were treated according to the European and American
scientific associations guidelines [26,27,28], by multidisciplinary
teams (one common team in Milan and one in Udine)
encompassing medical clinicians, surgeons (at liver transplant
centers), and interventional radiologists. Although the treatment
algorithm changed during the 12 years of the study, in particular
after the introduction of sorafenib in clinical practice for patients
with advanced disease, all centers had access to the full panel of
treatment options, and clinicians were unaware of the genetic
background of the patients, rendering the presence of a bias
unlikely.
As a reference group for the frequency distribution of the
I148M polymorphism in healthy patients without liver disease
(which did not allow to evaluate the effect of the I148M
polymorphism on HCC incidence), we considered 257 healthy
blood donors with normal liver enzymes (ALT ,35/30 IU/ml in
M/F, GGT ,35 IU/ml) and metabolic parameters, with a very
low probability of steatosis [30].
Informed written consent was obtained from each subject. The
study conforms to the ethical guidelines of the 1975 declaration of
Helsinki and was approved by the Institutional Review Board of
the Fondazione Ca’ Granda and participating centers.
Demographic and clinical features of subjects included are
presented in Table 1. The clinical features of patients with
complete clinical data and follow-up were not significantly
different from those of the other patients (Table S1).
Genetic analysis
The rs738409 C.G (I148M) PNPLA3 polymorphism was
genotyped in a blinded fashion on DNA specimens obtained by
peripheral blood by a 59nuclease Taqman assay (assay on demand
for rs738409, Applied Biosystems, Foster City, CA), as previously
described [14] at the Metabolic Liver Disease Laboratory at
Fondazione IRCCS Ca’ Granda. DNA was successfully extracted
and genotyped from each subject included in the study. Internal
controls were used in each batch analyzed.
Statistical analysis
Results are expressed as means 6 standard deviation or median
{interquartile range} according to data distribution. Mean values
were compared by Anova, and frequencies by Chi-square test,
according to data distribution, and differences were considered
significant when p#0.05 (two-tailed). Non-normally distributed
Table 1. Demographic, clinical, and genetic features of
subjects included in the study.
HCC Reference group
n= 460 257
Age years 6669 48612
Sex F 97 (21) 55 (21)
Diabetes 118 (26) 0
HCV 279 (61) 0
HBV 65 (14) 0
Alcohol abuse 80 (17) 0
Cirrhosis 442 (96) 0
PNPLA3 I148M
I/I 194 (42) 146 (57)
I/M 187 (41) 95 (37)
M/M 79 (17) 16 (6)
(): % values; HCC: hepatocellular carcinoma; HCV: chronic hepatitis C virus
infection, HBV: chronic hepatitis B virus infection (co-infected patients were
considered in both categories), F: female, PNPLA3: patatin-like phosholipase
domain-containing 3. p = 1.861026 for the frequency distribution of the I148M
polymorphism between HCC patients and controls.
doi:10.1371/journal.pone.0075982.t001
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PLOS ONE | www.plosone.org 2 October 2013 | Volume 8 | Issue 10 | e75982
variables were log-transformed before analysis. Based on the
previous literature, a recessive model was used to assess the
association of the I148M polymorphism with clinical presentation
of the patients and survival [25]. An additive model was also tested
for the association with clinical features of HCC patients at
diagnosis. The association between the PNPLA3 I148M polymor-
phism with HCC was evaluated by multivariate logistic regression
analysis adjusted for age and gender. The association between the
PNPLA3 I148M polymorphism and survival (recessive model) was
evaluated by Kaplan-Meier at univariate analysis (Log-rank test),
and Cox regression models adjusted for confounding variables,
which included those selected a priori for their biological relevance,
plus those which were found associated with the outcome of
interest at univariate analysis (specified in the Results section). P
values for model fitness were ,0.05. Our sample size had . 95%
power of detecting an association between PNPLA3 I148M and
survival with an OR of 2.0 with a significance of 5%. Analyses
were carried out with the statistical analysis software JMP 9.0 (SAS
Institute Inc, Cary, NC), and SPSS 19 (IBM, Armonk, NY).
Results
Frequency of I148M PNPLA3 polymorphism in patients
and healthy subjects
The frequency distribution of the I148M polymorphism was
significantly different between HCC patients and the reference
group (shown in Table 1; p = 1.861026), due to over-representa-
tion of homozygosity for the 148M allele (Table 1; p= 1.461025)
previously associated with steatosis. The association was also
evident in the 356 patients with complete data and follow-up
(Table S1; p = 9.461026 for the frequency distribution,
p = 4.461026 for the prevalence of 148M homozygosity).
I148M PNPLA3 polymorphism and etiology of HCC
Demographic, clinical, and genetic features of HCC patients
according to the etiology of liver disease are shown in Table S2.
Age at diagnosis, gender, and the severity of liver disease were
significantly different according to etiology. Interestingly, HCC
arose more frequently in patients without cirrhosis in patients with
NAFLD than in those with other etiologies (4/28, 14% vs. 13/432,
3%; p= 0.015).
The frequency distribution of the I148M was significantly
different according to the etiology of liver disease (p = 3.361027;
p = 1.561026 for 148M homozygosity). The prevalence of 148M
homozygosity in HCC patients with ALD&NAFLD and other
liver diseases and in healthy controls is shown in Figure S1.
Homozygosity for the 148M PNPLA3 variant was significantly
enriched in HCC patients, in particular in those with ALD&
NAFLD, but also in those with other liver diseases (ALD&
NAFLD: relative risk 5.9, 95% confidence interval (c.i.) 3.5–9.9;
Figure 1. Enrichment in 148M homozygosity in patients with
HCC vs. healthy controls. Relative risk and 95% confidence interval
(c.i.) of 148M homozygosity in patients with HCC associated with liver
diseases not directly related to steatohepatitis (non-ALD&NAFLD), and
patients with HCC related to liver disease related to steatohepatitis
(ALD&NAFLD).
doi:10.1371/journal.pone.0075982.g001
Table 2. Effect of I148M PNPLA3 variant on clinical presentation of HCC according to the etiology of liver disease (ALD & NAFLD
vs. other etiologies).
ALD & NAFLD Other liver diseases
PNPLA3 I148M I/I I/M M/M p value6 I/I I/M M/M p value6
n= 22 (20) 47 (44) 39 (36) - 172 (49) 140 (40) 40 (11) -
Age years 6767 6469 6266 0.018 67610 65610 6769 0.18
Sex F 4 (18) 8 (17) 3 (8) 0.37 36 (21) 37 (26) 9 (22) 0.59
Time from cirrhosis years 2 {1–7} 2 {0–6} 2 {0–3} 0.05 5{1–10} 4 {1–11} 5{2–12} 0.26
Diabetes 10 (45) 16 (34) 17 (44) 0.55 45 (34) 22 (29) 8 (28) 0.42
Cirrhosis 20 (91) 44 (94) 36 (92) 0.92 164 (96) 139 (99) 39 (98) 0.17
Child B/C 12 (55) 11 (23) 12 (31) 0.035 29 (16) 39 (42) 7 (18) 0.86
Lesion number* 1 {1–2} 1 {1–2.8} 1 {1–3.5} 0.007 1{1–2} 1{1–2} 1{1–3} 0.98
Major lesion mm* 20 {20–44} 25 {18–45} 30 {20–62} 0.32 25{18–30} 25 {20–40} 28 {18–36} 0.56
Very early
HCC*
8 (38) 12 (30) 10 (27) 0.39 45 (32) 24 (29) 9 (31) 0.89
Advanced
HCC**
14 (64) 19 (45) 27 (67) 0.07 71 (45) 70 (59) 14 (42) 0.36
(): % values, {}: median and interquartile range. HCC: hepatocellular carcinoma, ALD: alcoholic liver disease, NAFLD: nonalcoholic fatty liver disease, F: female, PNPLA3:
patatin-like phosholipase domain-containing 3. uAdditive model. * Available in 353 patients, ** available in 413 patients. Very early HCC and advanced / terminal HCC
were defined according to the updated Barcelona Clinic Liver Cancer (BCLC) staging system and EASL/EORTC guidelines [1].
doi:10.1371/journal.pone.0075982.t002
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other liver diseases: relative risk 1.9, 95% c.i. 1.1–3.4; Figure 1). At
logistic regression analysis, the association between 148M homo-
zygosity and HCC was independent of age and gender (OR 3.5,
95% c.i. 1.8–7.2, p = 2.361024), both in ALD&NAFLD (OR
10.6, 95% c.i. 4.8–25.3; p = 6.1610210), and in non ALD&-
NAFLD patients (OR 1.9, 95% c.i. 1.1–4.6; p = 0.05).
I148M PNPLA3 polymorphism and clinical presentation
of HCC
Due to the heterogeneity of disease etiologies influencing the
clinical presentation, we next evaluated the effect of I148M on
clinical presentation in patients subdivided according to the cause
of liver disease (ALD&NAFLD vs. other etiologies; Table 2). In
patients with ALD&NAFLD, PNPLA3 148M alleles were
associated with younger age at diagnosis of HCC (p= 0.018;
p = 0.040 under a recessive model), both in cirrhotic patients in
follow-up and in incident cases (p = 0.036 and p=0.044,
respectively). These results are in line with a shorter time from
the diagnosis of cirrhosis to HCC development in patients in
follow-up (p = 0.05 for ALD&NAFLD, p= 0.030 under a recessive
model). In addition, ALD&NAFLD patients carrying 148M alleles
tended to develop HCC at a less advanced stage of liver disease
(i.e. Child A cirrhosis: p = 0.035; p =ns at recessive model). The
association remained significant in patients in ALD&NAFLD
patients in regular follow-up (p= 0.042). Furthermore, the
PNPLA3 148M allele was associated with a higher number of
HCC lesions at presentation in ALD&NAFLD (p= 0.007;
p = 0.049 in cases diagnosed in regular follow-up).
In contrast, PNPLA3 genotype did not influence clinical
features at presentation in the overall series of HCC patients with
other liver diseases (Table 2). However, when we stratified patients
for the two major remaining etiologies (HBV and HCV, results are
shown in Table S3), in patients with HBV we observed that
PNPLA3 148M alleles were associated with younger age at
presentation (p = 0.011; p = 0.032 under a recessive model),
shorter time from cirrhosis to diagnosis (p = 0.045, p = 0.20 under
a recessive model), and with presentation of HCC at a less
advanced stage of liver disease (p = 0.032).
Histological diagnosis with the evaluation of HCC differentia-
tion grade was available in 118 patients. In this subset of patients,
PNPLA3 I148M was associated with higher Edmonson histolog-
ical grade in the overall series (Edmonson grade II-IV: 17/22,
77% vs. 50/96, 52%; p= 0.03). There was a significant association
between PNPLA3 148M homozygosity and higher HCC grade in
patients with ALD&NAFLD (10/12, 83% vs. 10/22, 45%;
p= 0.03), but not in those with other liver diseases (7/10, 70%
vs. 40/74, 54%; p= 0.3). These data are in line with more
aggressive histological and clinical presentation of HCC in
ALD&NAFLD patients homozygous for PNPLA3 148M.
I148M polymorphism and survival of HCC patients
Considering the overall cohort, PNPLA3 148M homozygotes
had a lower survival (p = 0.009 at Log-Rank test; median survival
36, 95% c.i. 30–42 vs. 48, 95% c.i. 43–52 months; Figure 2).
ALD&NAFLD patients had a worse survival compared to other
liver diseases (p = 261026 at Log-Rank test; median survival 36,
95% c.i. 29–43 vs. 55, 95% c.i. 44–66 months). After stratification
of patients according to the etiology of liver disease (ALD&-
NAFLD vs. others), homozygosity for PNPLA3 148M was
associated with lower survival in ALD&NAFLD (p= 0.003 at
Figure 2. Kaplan-Meier estimates for survival in HCC patients subdivided according to the presence of homozygosity for PNPLA3
148M (p = 0.009 at Log-Rank test). Figures at the bottom refer to the number of patients still under observation at each time interval. HR: hazard ratio
of death for homozygosity for the 148M allele, c.i.: confidence interval.
doi:10.1371/journal.pone.0075982.g002
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Figure 3. Kaplan-Meier estimates for survival in HCC patients subdivided according to the presence of homozygosity for PNPLA3
148M. Patients were stratified according to the etiology of liver disease: ALD&NAFLD (panel A; p = 0.003), and non-ALD&NAFLD (panel B; p = 0.86).
Figures at the bottom refer to the number of patients still under observation at each time interval. HR: hazard ratio of death for homozygosity for the
148M allele, c.i.: confidence interval.
doi:10.1371/journal.pone.0075982.g003
PNPLA3 and Clinical Features of HCC
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Figure 4. Kaplan-Meier estimates for survival in HCC patients subdivided according to the presence of homozygosity for PNPLA3
148M, stratified according to HCC stage at baseline. BCLC 0-A-B (panel A; p = 0.015), and BCLC stage C–D (panel B; p = 0.58). Figures at the
bottom refer to the number of patients still under observation at each time interval. HR: hazard ratio of death for homozygosity for the 148M allele,
c.i.: confidence interval.
doi:10.1371/journal.pone.0075982.g004
PNPLA3 and Clinical Features of HCC
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Log-Rank test; median survival 30, 95% c.i. 20–39 vs. 45, 95% c.i.
38–52 months; Figure 3A), but not in patients with other etiologies
(p = 0.86 at Log-Rank test; median survival 48, 95% c.i. 32–64 vs.
55, 95% c.i. 43–67 months; Figure 3B).
Patients with advanced stage (BCLC stage C–D) had a worse
survival compared to those presenting with less advanced,
including intermediate stage (BCLC stage 0-A-B) disease
(p = 9.261025 at Log-Rank test; median survival 42, 95% c.i.
36–45 vs. 48, 95% c.i. 48–67 months). After stratification of
patients according to the HCC stage at presentation (0-A-B vs. C–
D), homozygosity for PNPLA3 148M was associated with lower
survival in patients with less advanced (p= 0.015 at Log-Rank test;
median survival 36, 95% c.i. 30–48 vs. 54, 95% c.i. 48–72 months;
Figure 4A), but not in those with advanced disease (p = 0.57 at
Log-Rank test; median survival 36, 95% c.i. 24–48 vs. 42, 95% c.i.
30–48 months; Figure 4B).
Predictors of death at multivariate Cox regression analysis in
patients subdivided according to the etiology of liver disease
(ALD&NAFLD vs. others) are shown in Table 3.
In ALD&NAFLD, homozygosity for the PNPLA3 148M allele
was the only negative prognostic factor (hazard ratio (HR) 1.87,
95% c.i. 1.12–2.78), whereas in patients with other liver diseases,
age, advanced stage, and type 2 diabetes negatively influenced
survival.
Discussion
In this paper, we confirm previous reports indicating that the
PNPLA3 148M allele is a risk factor for HCC, in particular in
patients with ALD&NAFLD. We also report novel data suggesting
that HCCs arising in patients with ALD&NAFLD homozygous for
the 148M PNPLA3 allele present earlier during the natural history
of cirrhosis, are less differentiated, and have a larger diffusion at
presentation, and a worse prognosis.
The study was prompted by accumulating evidence that
PNPLA3 I148M influences both liver disease progression and
carcinogenesis, representing a potentially useful biomarker for
HCC risk stratification [3,4,5,6,7,8,9,10,31], whereas the clinical
implications of carrying the I148M polymorphism for patients
already diagnosed with HCC are still unknown.
Although the present study was not designed to evaluate the
association of the I148M polymorphism on HCC risk, in line with
previous results [3,4,5,6,7,8,9,10,31], the frequency of 148M was
higher in HCC patients than in controls without liver disease. In
particular, in ALD&NAFLD HCC patients, 148M homozygosity
was observed in about one in three subjects, and it was enriched
almost six-fold than in healthy control subjects. PNPLA3 148M
predisposes to fibrosis progression [4,18,32,33], but whether the
effect on carcinogenesis is independent of cirrhosis is still debated
[4,6,8,25,34]. On the other hand, data concordantly indicate that
the PNPLA3 148M predisposes to HCC in ALD, and is a risk
factor for HCC in obesity [3,5,6,7,8,25]. The association of
PNPLA3 148M with younger age, shorter history of cirrhosis, and
less advanced liver disease at HCC diagnosis in ALD&NAFLD is
therefore in line with direct carcinogenic activity of PNPLA3
148M, so that 148M homozygotes develop HCC before the other
complications of cirrhosis.
In ALD&NAFLD patients, PNPLA3 148M homozygosity was
associated with more diffuse HCC at diagnosis, as estimated by the
number of detected lesions, with more advanced grade in subset of
patients, and with reduced survival, representing the only
independent prognostic factor in these patients. Overall mortality
was chosen as the most appropriate outcome because is the most
solid and undisputable clinical endpoint, and in addition the
changes in treatment paradigm of HCC during the study period
would have confounded the evaluation of the outcome of specific
treatment approaches.
The effect of 148M homozygosity on survival was significant in
the overall cohort, and in patients with ALD&NAFLD. Further-
more, it was also evident in patients who did not present with
advanced or terminal HCC, suggesting that the 148M PNPLA3
allele may be associated with the development of more aggressive
HCC, which are not cured or are not amenable to be cured by
available therapies. Supporting our conclusions, after the submis-
sion of the present paper, it was independently reported that in
another retrospective-prospective case series of Caucasians HCC
patients from the US, who were mostly negative for HBV and
HCV infection, homozygosity for the 148M allele was indepen-
dently associated with reduced survival [35].
We cannot exclude that, especially in ALD where hepatic
failure represents a common cause of death [8], the I148M
polymorphism affected mortality by influencing the progression of
liver disease rather than that of HCC. However, homozygosity for
the 148M allele was more represented in younger patients with less
advanced liver disease at baseline, rendering less likely that it was
associated with excess mortality because of liver failure not
secondary to HCC progression.
Due to the heterogeneity of patients evaluated, of treatment
approaches, and the retrospective/prospective design, our results
need to be evaluated in prospective cohorts of selected patients
with early stages of HCC to minimize the effect of confounders,
such as different treatment modalities, to assess the usefulness of
the I148M polymorphism as a biomarker for stratification of HCC
patients.
In conclusion, PNPLA3 148M is over-represented in HCC
patients, in particular in those with ALD&NAFLD, where it is
Table 3. Independent predictors of death at multivariate Cox regression analysis in 356 patients with HCC with available follow-up
subdivided according to the etiology of underlying liver disease (ALD & NAFLD vs. others).
ALD & NAFLD
(n=101)
Other liver
diseases (n=255)
HR 95% c.i. p value HR 95% c.i. p value
Age years 1.00 0.97–1.03 0.94 1.02 1.00–1.04 0.05
Advanced stage 1.02 0.63–1.69 0.91 1.51 1.06–2.17 0.024
Diabetes 1.19 0.73–1.92 0.47 1.39 1.00–2.04 0.05
PNPLA3 148 MM 1.87 1.12–2.78 0.017 1.12 0.71–1.92 0.55
ALD: alcoholic liver disease, NAFLD: nonalcoholic fatty liver disease, Advanced stage: BCLC C-D, HR: hazard ratio of death, 95% c.i.: 95% confidence interval.
doi:10.1371/journal.pone.0075982.t003
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associated with earlier presentation at a less advanced stage of
liver disease. Furthermore, in ALD&NAFLD, PNPLA3 148M is
associated with more diffuse HCC at presentation, and with reduced
survival. Additional studies are required to evaluate the mechanisms
of hepatocarcinogenesis associated with PNPLA3 148M, and
whether this genetic is associated with a specific biological subtype
of HCC, and can predict the response to treatment.
Supporting Information
Figure S1 Prevalence of 148M homozygosity. In the
reference group of healthy subjects, patients with HCC associated
with liver diseases not directly related to steatohepatitis (non-
ALD&NAFLD), and patients with HCC related to liver disease
related to steatohepatitis (ALD&NAFLD).
(TIF)
Table S1 Demographic, clinical, and genetic features of
subjects with complete evaluation of the neoplastic
lesion at diagnosis, and with available follow-up,
included in the study.
(DOCX)
Table S2 Demographic, clinical, and genetic features of
HCC patients according to the etiology of liver disease.
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Table S3 Effect of I148M PNPLA3 variant on clinical
presentation of HCC in patients with chronic HBV or
chronic HBV infection.
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